Tarabay, A.; Boileve, A.; Smolenschi, C.; Antoun, L.; Valery, M.; Fuerea, A.; Perret, A.; Burtin, P.; Cosconea, S.; Belkhodja, H.;
et al. Precision Medicine in Pancreatic Ductal Adenocarcinoma: The Impact of Targeted Therapies on Survival of Patients Harboring Actionable Mutations. Biomedicines 2023, 11, 2569.
https://doi.org/10.3390/biomedicines11092569
AMA Style
Tarabay A, Boileve A, Smolenschi C, Antoun L, Valery M, Fuerea A, Perret A, Burtin P, Cosconea S, Belkhodja H,
et al. Precision Medicine in Pancreatic Ductal Adenocarcinoma: The Impact of Targeted Therapies on Survival of Patients Harboring Actionable Mutations. Biomedicines. 2023; 11(9):2569.
https://doi.org/10.3390/biomedicines11092569
Chicago/Turabian Style
Tarabay, Anthony, Alice Boileve, Cristina Smolenschi, Leony Antoun, Marine Valery, Alina Fuerea, Audrey Perret, Pascal Burtin, Simona Cosconea, Hichem Belkhodja,
and et al. 2023. "Precision Medicine in Pancreatic Ductal Adenocarcinoma: The Impact of Targeted Therapies on Survival of Patients Harboring Actionable Mutations" Biomedicines 11, no. 9: 2569.
https://doi.org/10.3390/biomedicines11092569
APA Style
Tarabay, A., Boileve, A., Smolenschi, C., Antoun, L., Valery, M., Fuerea, A., Perret, A., Burtin, P., Cosconea, S., Belkhodja, H., Malka, D., Boige, V., Hollebecque, A., & Ducreux, M.
(2023). Precision Medicine in Pancreatic Ductal Adenocarcinoma: The Impact of Targeted Therapies on Survival of Patients Harboring Actionable Mutations. Biomedicines, 11(9), 2569.
https://doi.org/10.3390/biomedicines11092569
